knowledge -WSS

knowledge

author：comprehensive 2025-09-30 00:46:49 - browse：9

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Prosthetic arm enables patients to feel the objects they grip

WSS

Psilocybin's anti

Scientists successfully use ultrasound imaging to map brain activity

AstraZeneca bets AAV gene therapy will still deliver the goods

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Health insurers say they are turning to AI to cut costs, improve care

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Continuity nursing helped my family in our darkest PICU moments

How to make AI work for medicine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Neuroscience startup Neumora files for IPO

United colonoscopy coverage change 'may cost lives,' doctors say

How a symptom of dementia informs our understanding of creativity

The high cost of giving birth even with insurance

iTeos Therapeutics debuts first data on TIGIT

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AstraZeneca challenges Medicare drug negotiation program

explore

Biohaven protein

iTeos Therapeutics debuts first data on TIGIT

What do new weight loss drugs mean for bariatric surgery?

Stigma and the return of syphilis

2024 GOP presidential candidates spar over abortion in debate

AstraZeneca bets AAV gene therapy will still deliver the goods

knowledge

focus

hotspot

explore